High prevalence of BRAF mutations in thyroid cancer: Genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma

Cancer Research

Volumn 63, Issue 7, 2003, Pages 1454-1457

  Kimura, Edna T ^a   Nikiforova, Marina N ^a   Zhu, Zhaowen ^a   Knauf, Jeffrey A ^a   Nikiforov, Yuri E ^a   Fagin, James A ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN RET; RAS PROTEIN; TYROSINE KINASE RECEPTOR;

ARTICLE; BRAF GENE; CONTROLLED STUDY; GENE; GENE MUTATION; GENE REARRANGEMENT; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL; SINGLE STRAND CONFORMATION POLYMORPHISM; THYROID PAPILLARY CARCINOMA;

CARCINOMA, PAPILLARY; CELL TRANSFORMATION, NEOPLASTIC; DROSOPHILA PROTEINS; EXONS; HUMANS; MUTATION; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS C-RAF; PROTO-ONCOGENE PROTEINS C-RET; RAS PROTEINS; RECEPTOR PROTEIN-TYROSINE KINASES; SIGNAL TRANSDUCTION; THYROID NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 0037379904     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Viglietto, G., Chiappetta, G., Martinez-Tello, F. J., Fukunaga, F. H., Tallini, G., Rigopoulou, D., Visconti, R., Mastro, A., Santoro, M., and Fusco, A. RET/PTC oncogene activation is an early event in thyroid carcinogenesis. Oncogene, 11: 1207-1210, 1995.
2. Fugazzola, L., Pilotti, S., Pinchera, A., Vorontsova, T. V., Mondellini, P., Bongarzone, I., Greco, A., Astakhova, L., Butti, M. G., Demidchik, E. P., and et al. Oncogenic rearrangements of the RET proto-oncogene in papillary thyroid carcinomas from children exposed to the Chernobyl nuclear accident. Cancer Res., 55: 5617-5620, 1995.
3. Nikiforov, Y. E., Rowland, J. M., Bove, K. E., Monforte-Munoz, H., and Fagin, J. A. Distinct pattern of ret oncogene rearrangements in morphological variants of radiation-induced and sporadic thyroid papillary carcinomas in children. Cancer Res., 57: 1690-1694, 1997.
4. Bounacer, A., Wicker, R., Caillou, B., Cailleux, A. F., Sarasin, A., Schlumberger, M., and Suarez, H. G. High prevalence of activating ret proto-oncogene rearrangements, in thyroid tumors from patients who had received external radiation. Oncogene, 15: 1263-1273, 1997.
5. Klugbauer, S., Lengfelder, E., Demidchik, E. P., and Rabes, H. M. High prevalence of RET rearrangement in thyroid tumors of children from Belarus after the Chernobyl reactor accident. Oncogene, 11: 2459-2467, 1995.
6. Nikiforova, M. N., Stringer, J. R., Blough, R., Medvedovic, M., Fagin, J. A., and Nikiforov, Y. E. Proximity of chromosomal loci that participate in radiation-induced rearrangements in human cells. Science (Wash. DC), 290: 138-141, 2000.
7. Pierotti, M. A., Bongarzone, I., Borrello, M. G., Mariani, C., Miranda, C., Sozzi, G., and Greco, A. Rearrangements of TRK proto-oncogene in papillary thyroid carcinomas. J. Endocrinol. Investig., 18: 130-133, 1995.
8. Namba, H., Rubin, S. A., and Fagin, J. A. Point mutations of ras oncogenes are an early event in thyroid tumorigenesis. Mol. Endocrinol., 4: 1474-1479, 1990.
9. Asai, N., Murakami, H., Iwashita, T., and Takahashi, M. A mutation at tyrosine 1062 in MEN2A-Ret and MEN2B-Ret impairs their transforming activity and association with shc adaptor proteins. J. Biol. Chem., 271: 17644-17649, 1996.
10. Daum, G., Eisenmann-Tappe, I., Fries, H. W., Troppmair, J., and Rapp, U. R. The ins and outs of Raf kinases. Trends Biochem. Sci., 19: 474-480, 1994.
11. Peyssonnaux, C., and Eychene, A. The Raf/MEK/ERK pathway: new concepts of activation. Biol. Cell., 93: 53-62, 2001.
12. Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., Davis, N., Dicks, E., Ewing, R., Floyd, Y., Gray, K., Hall, S., Hawes, R., Hughes, J., Kosmidou, V., Menzies, A., Mould, C., Parker, A., Stevens, C., Watt, S., Hooper, S., Wilson, R., Jayatilake, H., Gusterson, B. A., Cooper, C., Shipley, J., Hargrave, D., Pritchard-Jones, K., Maitland, N., Chenevix-Trench, G., Riggins, G. J., Bigner, D. D., Palmieri, G., Cossu, A., Flanagan, A., Nicholson, A., Ho, J. W., Leung, S. Y., Yuen, S. T., Weber, B. L., Seigler, H. F., Darrow, T. L., Paterson, H., Marais, R., Marshall, C. J., Wooster, R., Stratton, M. R., and Futreal, P. A. Mutations of the BRAF gene in human cancer. Nature (Lond.), 417: 949-954, 2002.
13. Rajagopalan, H., Bardelli, A., Lengauer, C., Kinzler, K. W., Vogelstein, B., and Velculescu, V. E. Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature (Lond.), 418: 934, 2002.
14. Fagin, J. A., Matsuo, K., Karmakar, A., Chen, D. L., Tang, S. H., and Koeffler, H. P. High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas. J. Clin. Investig., 91: 179-184, 1993.
15. Nikiforov, Y. E., Nikiforova, M. N., Gnepp, D. R., and Fagin, J. A. Prevalence of mutations of ras and p53 in benign and malignant thyroid tumors from children exposed to radiation after the Chernobyl nuclear accident. Oncogene, 13: 687-693, 1996.
16. Zeki, K., Spambalg, D., Sharifi, N., Gonsky, R., and Fagin, J. A. Mutations of the adenomatous polyposis coli gene in sporadic thyroid neoplasms. J. Clin. Endocrinol., 79: 1317-1321, 1994.
17. Tatusova, T. A., and Madden, T. L. BLAST 2 Sequences, a new tool for comparing protein and nucleotide sequences. FEMS Microbiol. Lett., 174: 247-250, 1999.
18. Elenitoba-Johnson, K. S., Bohling, S. D., Wittwer, C. T., and King, T. C. Multiplex PCR by multicolor fluorimetry and fluorescence melting curve analysis. Nat. Med., 7: 249-253, 2001.
19. Nikiforova, M. N., Lynch, R. A., Biddinger, P. W., Alexander, E. K., Dorn, G. W., Tallini, G., Kroll, T. G., and Nikiforov, Y. E. RAS point mutations and PAX8-PPARγ rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma. J. Clin. Endocrinol. Metab., in press, 2003.
20. Santoro, M., Carlomagno, F., Hay, I. D., Herrmann, M. A., Grieco, M., Melillo, R., Pierotti, M. A., Bongarzone, I., Della Porta, G., Berger, N., and et al. Ret oucogene activation in human thyroid neoplasms is restricted to the papillary cancer subtype. J. Clin. Investig., 89: 1517-1522, 1992.
21. Santoro, M., Melillo, R. M., Grieco, M., Berlingieri, M. T., Vecchio, G., and Fusco, A. The TRK and RET tyrosine kinase oncogenes cooperate with ras in the neoplastic transformation of a rat thyroid epithelial cell line. Cell Growth Differ., 4: 77-84, 1993.
22. Santoro, M., Melillo, R. M., Carlomagno, F., Fusco, A., and Vecchio, G. Molecular mechanisms of RET activation in human cancer. Ann. N. Y. Acad. Sci., 963: 116-121, 2002.
23. Klugbauer, S., Pfeiffer, P., Gassenhuber, H., Beimfohr, C., and Rabes, H. M. RET rearrangements in radiation-induced papillary thyroid carcinomas: high prevalence of topoisomerase I sites at breakpoints and microhomology-mediated end joining in ELE1 and RET chimeric genes. Genomics, 73: 149-160, 2001.
24. Fugazzola, L., Pierotti, M. A., Vigano, E., Pacini, F., Vorontsova, T. V., and Bongarzone, I. Molecular and biochemical analysis of RET/PTC4, a novel oncogenic rearrangement between RET and ELE1 genes, in a post-Chernobyl papillary thyroid cancer. Oncogene. 13: 1093-1097, 1996.
25. Nikiforov, Y. E., Koshoffer, A., Nikiforova, M., Stringer, J., and Fagin, J. A. Chromosomal breakpoint positions suggest a direct role for radiation in inducing illegitimate recombination between the ELE1 and RET genes in radiation-induced thyroid carcinomas. Oncogene, 18: 6330-6334, 1999.
26. Ribeiro-Neto, F., Urbani, J., Lemee, N., Lou, L., and Altschuler, D. L. On the mitogenic properties of Rap1b: cAMP-induced G(1)/S entry requires activated and phosphorylated Rap1b. Proc. Natl. Acad. Sci. USA, 99: 5418-5423, 2002.
27. Busca, R., Abbe, P., Mantoux, F., Aberdam, E., Peyssonnaux, C., Eychene, A., Ortonne, J. P., and Ballotti, R. Ras mediates the cAMP-dependent activation of extracellular signal- regulated kinases (ERKs) in melanocytes. EMBO J., 19: 2900-2910, 2000.
28. Tsygankova, O. M., Kupperman, E., Wen, W., and Meinkoth, J. L. Cyclic AMP activates Ras. Oncogene, 19: 3609-3615, 2000.
29. Iacovelli, L., Capobianco, L., Salvatore, L., Sallese, M., D'Ancona, G. M., and De Blasi, A. Thyrotropin activates mitogen-activated protein kinase pathway in FRTL- 5 by a cAMP-dependent protein kinase A-independent mechanism. Mol. Pharmacol., 60: 924-933, 2001.
30. Esapa, C. T., Johnson, S. J., Kendall-Taylor, P., Lennard, T. W., and Harris, P. E. Prevalence of Ras mutations in thyroid neoplasia. Clin. Endocrinol. (Oxf.), 50: 529-535, 1999.